Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy
Although chimeric antigen receptor T-cell (CAR-T) therapy produces a high complete remission rate among patients with relapsed/refractory B-cell acute lymphoblastic leukemia, relapse remains an urgent issue. It is uncertain whether consolidative haploidentical-allogeneic hematopoietic stem cell tran...
Saved in:
| Published in | Leukemia Vol. 35; no. 11; pp. 3092 - 3100 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.11.2021
Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Although chimeric antigen receptor T-cell (CAR-T) therapy produces a high complete remission rate among patients with relapsed/refractory B-cell acute lymphoblastic leukemia, relapse remains an urgent issue. It is uncertain whether consolidative haploidentical-allogeneic hematopoietic stem cell transplantation (haplo-HSCT) is suitable for achieving sustainable remission. Therefore, we aimed to assess the efficacy and safety of bridging CAR-T therapy to haplo-HSCT. Fifty-two patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who underwent haplo-HSCT after CAR-T therapy were analyzed. The median time from CAR-T therapy to haplo-HSCT was 61 days. After a median follow-up of 24.6 months, the 1-year probabilities of event-free survival, overall survival, and cumulative incidence of relapse were 80.1% (95% confidence interval (CI), 69.0–90.9), 92.3% (95% CI, 85.0–99.5), and 14.1% (95% CI, 10.7–17.4), respectively, while the corresponding 2-year probabilities were 76.0% (95% CI, 64.2–87.7), 84.3% (95% CI, 74.3–94.3), and 19.7% (95% CI, 15.3–24.0), respectively. No increased risk of 2-year cumulative incidence of graft-versus-host disease, treatment-related mortality, or infection was observed. A pre-HSCT measurable residual disease-positive status was an independent factor associated with poor overall survival (hazard radio: 4.201, 95% CI: 1.034–17.063;
P
= 0.045). Haplo-HSCT may be a safe and effective treatment strategy to improve event-free survival and overall survival after CAR-T therapy. |
|---|---|
| AbstractList | Although chimeric antigen receptor T-cell (CAR-T) therapy produces a high complete remission rate among patients with relapsed/refractory B-cell acute lymphoblastic leukemia, relapse remains an urgent issue. It is uncertain whether consolidative haploidentical-allogeneic hematopoietic stem cell transplantation (haplo-HSCT) is suitable for achieving sustainable remission. Therefore, we aimed to assess the efficacy and safety of bridging CAR-T therapy to haplo-HSCT. Fifty-two patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who underwent haplo-HSCT after CAR-T therapy were analyzed. The median time from CAR-T therapy to haplo-HSCT was 61 days. After a median follow-up of 24.6 months, the 1-year probabilities of event-free survival, overall survival, and cumulative incidence of relapse were 80.1% (95% confidence interval (CI), 69.0-90.9), 92.3% (95% CI, 85.0-99.5), and 14.1% (95% CI, 10.7-17.4), respectively, while the corresponding 2-year probabilities were 76.0% (95% CI, 64.2-87.7), 84.3% (95% CI, 74.3-94.3), and 19.7% (95% CI, 15.3-24.0), respectively. No increased risk of 2-year cumulative incidence of graft-versus-host disease, treatment-related mortality, or infection was observed. A pre-HSCT measurable residual disease-positive status was an independent factor associated with poor overall survival (hazard radio: 4.201, 95% CI: 1.034-17.063; P = 0.045). Haplo-HSCT may be a safe and effective treatment strategy to improve event-free survival and overall survival after CAR-T therapy.Although chimeric antigen receptor T-cell (CAR-T) therapy produces a high complete remission rate among patients with relapsed/refractory B-cell acute lymphoblastic leukemia, relapse remains an urgent issue. It is uncertain whether consolidative haploidentical-allogeneic hematopoietic stem cell transplantation (haplo-HSCT) is suitable for achieving sustainable remission. Therefore, we aimed to assess the efficacy and safety of bridging CAR-T therapy to haplo-HSCT. Fifty-two patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who underwent haplo-HSCT after CAR-T therapy were analyzed. The median time from CAR-T therapy to haplo-HSCT was 61 days. After a median follow-up of 24.6 months, the 1-year probabilities of event-free survival, overall survival, and cumulative incidence of relapse were 80.1% (95% confidence interval (CI), 69.0-90.9), 92.3% (95% CI, 85.0-99.5), and 14.1% (95% CI, 10.7-17.4), respectively, while the corresponding 2-year probabilities were 76.0% (95% CI, 64.2-87.7), 84.3% (95% CI, 74.3-94.3), and 19.7% (95% CI, 15.3-24.0), respectively. No increased risk of 2-year cumulative incidence of graft-versus-host disease, treatment-related mortality, or infection was observed. A pre-HSCT measurable residual disease-positive status was an independent factor associated with poor overall survival (hazard radio: 4.201, 95% CI: 1.034-17.063; P = 0.045). Haplo-HSCT may be a safe and effective treatment strategy to improve event-free survival and overall survival after CAR-T therapy. Although chimeric antigen receptor T-cell (CAR-T) therapy produces a high complete remission rate among patients with relapsed/refractory B-cell acute lymphoblastic leukemia, relapse remains an urgent issue. It is uncertain whether consolidative haploidentical-allogeneic hematopoietic stem cell transplantation (haplo-HSCT) is suitable for achieving sustainable remission. Therefore, we aimed to assess the efficacy and safety of bridging CAR-T therapy to haplo-HSCT. Fifty-two patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who underwent haplo-HSCT after CAR-T therapy were analyzed. The median time from CAR-T therapy to haplo-HSCT was 61 days. After a median follow-up of 24.6 months, the 1-year probabilities of event-free survival, overall survival, and cumulative incidence of relapse were 80.1% (95% confidence interval (CI), 69.0-90.9), 92.3% (95% CI, 85.0-99.5), and 14.1% (95% CI, 10.7-17.4), respectively, while the corresponding 2-year probabilities were 76.0% (95% CI, 64.2-87.7), 84.3% (95% CI, 74.3-94.3), and 19.7% (95% CI, 15.3-24.0), respectively. No increased risk of 2-year cumulative incidence of graft-versus-host disease, treatment-related mortality, or infection was observed. A pre-HSCT measurable residual disease-positive status was an independent factor associated with poor overall survival (hazard radio: 4.201, 95% CI: 1.034-17.063; P = 0.045). Haplo-HSCT may be a safe and effective treatment strategy to improve event-free survival and overall survival after CAR-T therapy. Although chimeric antigen receptor T-cell (CAR-T) therapy produces a high complete remission rate among patients with relapsed/refractory B-cell acute lymphoblastic leukemia, relapse remains an urgent issue. It is uncertain whether consolidative haploidentical-allogeneic hematopoietic stem cell transplantation (haplo-HSCT) is suitable for achieving sustainable remission. Therefore, we aimed to assess the efficacy and safety of bridging CAR-T therapy to haplo-HSCT. Fifty-two patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who underwent haplo-HSCT after CAR-T therapy were analyzed. The median time from CAR-T therapy to haplo-HSCT was 61 days. After a median follow-up of 24.6 months, the 1-year probabilities of event-free survival, overall survival, and cumulative incidence of relapse were 80.1% (95% confidence interval (CI), 69.0–90.9), 92.3% (95% CI, 85.0–99.5), and 14.1% (95% CI, 10.7–17.4), respectively, while the corresponding 2-year probabilities were 76.0% (95% CI, 64.2–87.7), 84.3% (95% CI, 74.3–94.3), and 19.7% (95% CI, 15.3–24.0), respectively. No increased risk of 2-year cumulative incidence of graft-versus-host disease, treatment-related mortality, or infection was observed. A pre-HSCT measurable residual disease-positive status was an independent factor associated with poor overall survival (hazard radio: 4.201, 95% CI: 1.034–17.063; P = 0.045). Haplo-HSCT may be a safe and effective treatment strategy to improve event-free survival and overall survival after CAR-T therapy. |
| Audience | Academic |
| Author | Jia, Yue-Ping Li, Ying-Chun Zuo, Ying-Xi Zhao, Xiang-Yu Wang, Yu Cheng, Yi-Fei Jiao, Shun-Chang Kong, Jun Yan, Chen-Hua Zhang, Long-Ji Wu, Jun Zhang, Le-Ping Chang, Ying-Jun Lu, Ai-Dong Zhang, Xiao-Hui Xu, Lan-Ping Liu, Kai-Yan Huang, Xiao-Jun Hu, Guan-Hua Suo, Pan |
| Author_xml | – sequence: 1 givenname: Guan-Hua surname: Hu fullname: Hu, Guan-Hua organization: Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences – sequence: 2 givenname: Xiang-Yu surname: Zhao fullname: Zhao, Xiang-Yu organization: Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences – sequence: 3 givenname: Ying-Xi surname: Zuo fullname: Zuo, Ying-Xi organization: Department of Pediatrics, Peking University People’s Hospital, Peking University – sequence: 4 givenname: Ying-Jun orcidid: 0000-0002-6124-6050 surname: Chang fullname: Chang, Ying-Jun organization: Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences – sequence: 5 givenname: Pan surname: Suo fullname: Suo, Pan organization: Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences – sequence: 6 givenname: Jun surname: Wu fullname: Wu, Jun organization: Department of Pediatrics, Peking University People’s Hospital, Peking University – sequence: 7 givenname: Yue-Ping surname: Jia fullname: Jia, Yue-Ping organization: Department of Pediatrics, Peking University People’s Hospital, Peking University – sequence: 8 givenname: Ai-Dong surname: Lu fullname: Lu, Ai-Dong organization: Department of Pediatrics, Peking University People’s Hospital, Peking University – sequence: 9 givenname: Ying-Chun surname: Li fullname: Li, Ying-Chun organization: Beijing Yongtai Reike Biotechnology Company Ltd – sequence: 10 givenname: Yu surname: Wang fullname: Wang, Yu organization: Beijing Yongtai Reike Biotechnology Company Ltd – sequence: 11 givenname: Shun-Chang surname: Jiao fullname: Jiao, Shun-Chang organization: Chinese People Liberation Army (PLA) General Hospital – sequence: 12 givenname: Long-Ji surname: Zhang fullname: Zhang, Long-Ji organization: Shenzhen Geno-immune Medical Institute – sequence: 13 givenname: Jun surname: Kong fullname: Kong, Jun organization: Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences – sequence: 14 givenname: Chen-Hua surname: Yan fullname: Yan, Chen-Hua organization: Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences – sequence: 15 givenname: Lan-Ping surname: Xu fullname: Xu, Lan-Ping organization: Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences – sequence: 16 givenname: Xiao-Hui surname: Zhang fullname: Zhang, Xiao-Hui organization: Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences – sequence: 17 givenname: Kai-Yan surname: Liu fullname: Liu, Kai-Yan organization: Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences – sequence: 18 givenname: Yi-Fei orcidid: 0000-0003-2894-9034 surname: Cheng fullname: Cheng, Yi-Fei email: chengyifei182@sina.com organization: Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences – sequence: 19 givenname: Yu orcidid: 0000-0003-1253-7465 surname: Wang fullname: Wang, Yu email: ywyw3172@sina.com organization: Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences – sequence: 20 givenname: Le-Ping surname: Zhang fullname: Zhang, Le-Ping organization: Department of Pediatrics, Peking University People’s Hospital, Peking University – sequence: 21 givenname: Xiao-Jun surname: Huang fullname: Huang, Xiao-Jun organization: Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33824464$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl1r1jAUx4tM3It-AS8kIIg33ZKmTdvL7cE3GCiyXZez5PRpZprUJBX7lf0Upnumc0NGL0KT3y_ncPI_zPass5hlLxk9ZpQ3J6FkvK5yWrCcsoKLfHmSHbCyFnlVVWwvO6BNU-eiLcr97DCEa0rXQ_Es2-e8KcpSlAfZr0s7gtXTbCCiIgNMxmmFNmoJhgw4QnST05j-SYg4EonGkOjBhsmAjRC1s0QHApbgz_UwucRNN9u980QO2iiPNgGKLG62WwJqNpF4NDAFVCceew8yOr-QLwkGhWYaNCTTu9EFN2JucZsK_UBylt_UBzlHJGYZp8FdGQhrdwbnbzgmD_qInmxOv-YXOzoO6GFanmdPezABX9yuR9nl-3cXm4_5-ecPnzan57ksax7zXlayopQXUDMmKG9VVQsshGCqkj3HWqn2ClQDVJZtofpW8KZBqQRUKBql-FH2dnfv5N33GUPsRh3WRsCim0NXVLQVVDSlSOjrB-i1m71N3SWqEaIWrSjvqC0Y7LTtXZq_XC_tTkVDS16zgiXq-D9U-lSaikzJ6XXavye8-UcYEEwcgjPz-nThPvjqtsv5akTVTV6P4JfuT4oSUOwA6V0I6T3_Iox2a1S7XVS7FNXuJqrdkqTmgST1Lk6pb20eV_lODamO3aK_G9sj1m-RawLQ |
| CitedBy_id | crossref_primary_10_1080_17474086_2022_2125375 crossref_primary_10_1016_j_jtct_2021_11_011 crossref_primary_10_3390_ijms25126380 crossref_primary_10_1097_CM9_0000000000001898 crossref_primary_10_1097_CM9_0000000000002945 crossref_primary_10_1111_ctr_15247 crossref_primary_10_1038_s41375_021_01351_w crossref_primary_10_1016_j_canlet_2025_217542 crossref_primary_10_1002_ajh_26506 crossref_primary_10_3389_fped_2022_807992 crossref_primary_10_3389_fped_2022_923419 crossref_primary_10_3389_fimmu_2022_934442 crossref_primary_10_3389_fimmu_2022_954235 crossref_primary_10_1155_2024_3091760 crossref_primary_10_1007_s40278_022_10218_8 crossref_primary_10_1016_j_blre_2022_101035 crossref_primary_10_1200_EDBK_349647 crossref_primary_10_1097_MPH_0000000000002861 crossref_primary_10_1111_bjh_19086 crossref_primary_10_1080_08880018_2024_2408535 crossref_primary_10_1097_CM9_0000000000002764 crossref_primary_10_1016_S2352_3026_22_00293_9 crossref_primary_10_3389_fonc_2023_1116205 crossref_primary_10_7889_tct_21_019 crossref_primary_10_1038_s41409_022_01688_5 crossref_primary_10_4143_crt_2023_1205 |
| Cites_doi | 10.1038/leu.2017.145 10.1016/S1470-2045(12)70580-6 10.1182/bloodadvances.2019000593 10.1056/NEJMra1400972 10.1002/ajh.25417 10.1007/s10555-019-09834-0 10.1186/s13045-014-0059-3 10.1186/s13045-019-0781-y 10.1182/blood.2019001641 10.1002/ajh.25582 10.1016/j.bbmt.2014.08.023 10.1016/j.bbmt.2018.03.015 10.1080/10428194.2019.1605071 10.1182/blood-2014-05-552729 10.3324/haematol.2012.073189 10.1002/cpt.1674 10.1111/bjh.15086 10.1182/blood-2015-02-627786 10.1016/S0140-6736(14)61403-3 10.1056/NEJMoa1709866 10.1038/bmt.2014.109 10.1111/bjh.16339 10.1126/scitranslmed.3008226 10.1016/j.bbmt.2008.02.007 10.1182/blood-2018-11-883710 10.1002/pbc.28149 10.1158/1078-0432.CCR-18-0758 10.1111/bjh.13142 10.1182/blood-2011-12-399287 10.1186/s13045-018-0564-x |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Nature Limited 2021 2021. The Author(s), under exclusive licence to Springer Nature Limited. COPYRIGHT 2021 Nature Publishing Group The Author(s), under exclusive licence to Springer Nature Limited 2021. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Nature Limited 2021 – notice: 2021. The Author(s), under exclusive licence to Springer Nature Limited. – notice: COPYRIGHT 2021 Nature Publishing Group – notice: The Author(s), under exclusive licence to Springer Nature Limited 2021. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T5 7T7 7TM 7TO 7U9 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7N M7P NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1038/s41375-021-01236-y |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Database ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest Central Student MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1476-5551 |
| EndPage | 3100 |
| ExternalDocumentID | A680437121 33824464 10_1038_s41375_021_01236_y |
| Genre | Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GroupedDBID | --- -Q- .55 .XZ 0R~ 29L 2WC 36B 39C 3V. 4.4 406 53G 5GY 5RE 70F 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 AACDK AANZL AAQQT AASDW AASML AATNV AAWTL AAYZH AAZLF ABAKF ABAWZ ABDBF ABJNI ABLJU ABOCM ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMJI ACPRK ACRQY ACUHS ACZOJ ADBBV ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFFNX AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF ASPBG AVWKF AXYYD AZFZN B0M BAWUL BBNVY BENPR BHPHI BKEYQ BKKNO BPHCQ BVXVI CAG CCPQU COF CS3 DIK DNIVK DPUIP DU5 E3Z EAD EAP EBC EBD EBLON EBS EBX EE. EIOEI EJD EMB EMK EMOBN EPL ESX EX3 F5P FDQFY FEDTE FERAY FIGPU FIZPM FSGXE FYUFA HCIFZ HMCUK HVGLF HZ~ IAO IH2 IHR IHW INH INR ITC IWAJR JSO JZLTJ KQ8 LGEZI LOTEE M1P M7P N9A NADUK NAO NAPCQ NQJWS NXXTH O9- OK1 OVD P2P P6G PQQKQ PROAC PSQYO Q2X RNS RNT RNTTT ROL SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TEORI TR2 TSG TUS UDS UKHRP WOW X7M Y6R ZGI ZXP ~8M AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC AEZWR AFDZB AFHIU AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM AEIIB PMFND 7QL 7T5 7T7 7TM 7TO 7U9 7XB 8FD 8FE 8FH 8FK ABRTQ AZQEC C1K DWQXO FR3 GNUQQ H94 K9. LK8 M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c473t-fc5c50032a7116039d576e2661d5cf3e7dd9bad8a0c492df96388ecd6a5e68dd3 |
| IEDL.DBID | 7X7 |
| ISSN | 0887-6924 1476-5551 |
| IngestDate | Fri Jul 11 13:25:15 EDT 2025 Fri Jul 25 09:03:03 EDT 2025 Tue Jun 17 22:13:52 EDT 2025 Tue Jun 10 21:08:52 EDT 2025 Thu May 22 21:25:27 EDT 2025 Wed Feb 19 02:27:48 EST 2025 Tue Jul 01 01:08:09 EDT 2025 Thu Apr 24 23:04:28 EDT 2025 Fri Feb 21 02:37:55 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | 2021. The Author(s), under exclusive licence to Springer Nature Limited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c473t-fc5c50032a7116039d576e2661d5cf3e7dd9bad8a0c492df96388ecd6a5e68dd3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-2894-9034 0000-0002-6124-6050 0000-0003-1253-7465 |
| PMID | 33824464 |
| PQID | 2586676964 |
| PQPubID | 30521 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_2509606846 proquest_journals_2586676964 gale_infotracmisc_A680437121 gale_infotracacademiconefile_A680437121 gale_healthsolutions_A680437121 pubmed_primary_33824464 crossref_primary_10_1038_s41375_021_01236_y crossref_citationtrail_10_1038_s41375_021_01236_y springer_journals_10_1038_s41375_021_01236_y |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-11-01 |
| PublicationDateYYYYMMDD | 2021-11-01 |
| PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Leukemia |
| PublicationTitleAbbrev | Leukemia |
| PublicationTitleAlternate | Leukemia |
| PublicationYear | 2021 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Hunger, Mullighan (CR3) 2015; 373 Gokbuget, Stanze, Beck, Diedrich, Horst, Huttmann (CR5) 2012; 120 Holstein, Lunning (CR19) 2020; 107 Wang, Wu, Liu, Xu, Liu, Zhang (CR18) 2019; 12 Pan, Yang, Deng, Zhao, Zhang, Lin (CR24) 2017; 31 Harris, Kitko, Couriel, Braun, Choi, Magenau (CR25) 2013; 98 Hay, Gauthier, Hirayama, Voutsinas, Wu, Li (CR11) 2019; 133 Zhao, Zhao, Chen, Qin, Xu, Zhang (CR29) 2018; 24 Davila, Riviere, Wang, Bartido, Park, Curran (CR8) 2014; 6 Wang, Liu, Xu, Liu, Zhang, Ma (CR13) 2015; 125 Lai, Chen, Hu, Jiang, Liu, Liu (CR17) 2014; 7 Lee, Gardner, Porter, Louis, Ahmed, Jensen (CR12) 2014; 124 Mo, Kong, Zhao, Xu, Zhang, Liu (CR26) 2014; 20 Liu, Huang, Liu, Xu, Chen, Han (CR16) 2008; 14 Shadman, Gauthier, Hay, Voutsinas, Milano, Li (CR27) 2019; 3 Inaba, Pui (CR2) 2019; 38 Mo, Zhao, Liu, Chen, Xu, Zhang (CR14) 2014; 49 Xu, Chen, Chen, Han, Huang, Lai (CR15) 2018; 11 Mueller, Waldron, Grupp, Levine, Laetsch, Pulsipher (CR22) 2018; 24 Lee, Kochenderfer, Stetler-Stevenson, Cui, Delbrook, Feldman (CR9) 2015; 385 Sutton, Shaw, Venn, Law, Dissanayake, Kilo (CR6) 2015; 168 Shalabi, Yuan, Kulshreshtha, Dulau-Florea, Salem, Gupta (CR20) 2020; 67 Maude, Laetsch, Buechner, Rives, Boyer, Bittencourt (CR10) 2018; 378 Lovisa, Zecca, Rossi, Campeggio, Magrin, Giarin (CR7) 2018; 180 Rafei, Kantarjian, Jabbour (CR1) 2019; 60 Zhang, Chen, Song, Tan, Zhao, Liu (CR30) 2020; 189 Bhojwani, Pui (CR4) 2013; 14 Jiang, Li, Yin, Guo, Liu, Xia (CR23) 2019; 94 Zhao, Liu, Xu, Wang, Zhang, Chen (CR28) 2019; 94 Curran, Margossian, Kernan, Silverman, Williams, Shukla (CR21) 2019; 134 AC Harris (1236_CR25) 2013; 98 H Rafei (1236_CR1) 2019; 60 XD Mo (1236_CR14) 2014; 49 KJ Curran (1236_CR21) 2019; 134 XS Zhao (1236_CR28) 2019; 94 KT Mueller (1236_CR22) 2018; 24 SL Maude (1236_CR10) 2018; 378 R Sutton (1236_CR6) 2015; 168 DW Lee (1236_CR12) 2014; 124 M Shadman (1236_CR27) 2019; 3 SP Hunger (1236_CR3) 2015; 373 DW Lee (1236_CR9) 2015; 385 X Zhao (1236_CR29) 2018; 24 L Xu (1236_CR15) 2018; 11 Y Zhang (1236_CR30) 2020; 189 H Inaba (1236_CR2) 2019; 38 H Jiang (1236_CR23) 2019; 94 F Lovisa (1236_CR7) 2018; 180 D Liu (1236_CR16) 2008; 14 J Pan (1236_CR24) 2017; 31 ML Davila (1236_CR8) 2014; 6 Y Wang (1236_CR18) 2019; 12 N Gokbuget (1236_CR5) 2012; 120 YR Lai (1236_CR17) 2014; 7 XD Mo (1236_CR26) 2014; 20 SA Holstein (1236_CR19) 2020; 107 D Bhojwani (1236_CR4) 2013; 14 KA Hay (1236_CR11) 2019; 133 H Shalabi (1236_CR20) 2020; 67 Y Wang (1236_CR13) 2015; 125 |
| References_xml | – volume: 31 start-page: 2587 year: 2017 end-page: 93 ident: CR24 article-title: High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients publication-title: Leukemia. doi: 10.1038/leu.2017.145 – volume: 14 start-page: e205 year: 2013 end-page: 17 ident: CR4 article-title: Relapsed childhood acute lymphoblastic leukaemia publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70580-6 – volume: 3 start-page: 3062 year: 2019 end-page: 9 ident: CR27 article-title: Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy publication-title: Blood Adv. doi: 10.1182/bloodadvances.2019000593 – volume: 373 start-page: 1541 year: 2015 end-page: 52 ident: CR3 article-title: Acute lymphoblastic leukemia in children publication-title: N Engl J Med. doi: 10.1056/NEJMra1400972 – volume: 94 start-page: 512 year: 2019 end-page: 21 ident: CR28 article-title: Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts publication-title: Am J Hematol doi: 10.1002/ajh.25417 – volume: 38 start-page: 595 year: 2019 end-page: 610 ident: CR2 article-title: Immunotherapy in pediatric acute lymphoblastic leukemia publication-title: Cancer Metastasis Rev. doi: 10.1007/s10555-019-09834-0 – volume: 7 start-page: 59 year: 2014 ident: CR17 article-title: Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG) publication-title: J Hematol Oncol doi: 10.1186/s13045-014-0059-3 – volume: 12 start-page: 88 year: 2019 ident: CR18 article-title: Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients publication-title: J Hematol Oncol doi: 10.1186/s13045-019-0781-y – volume: 134 start-page: 2361 year: 2019 end-page: 8 ident: CR21 article-title: Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL publication-title: Blood. doi: 10.1182/blood.2019001641 – volume: 94 start-page: 1113 year: 2019 end-page: 22 ident: CR23 article-title: Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial publication-title: Am J Hematol doi: 10.1002/ajh.25582 – volume: 20 start-page: 2023 year: 2014 end-page: 8 ident: CR26 article-title: Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes publication-title: Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2014.08.023 – volume: 24 start-page: 1936 year: 2018 end-page: 43 ident: CR29 article-title: Comparative analysis of flow cytometry and RQ-PCR for the detection of minimal residual disease in philadelphia chromosome-positive acute lymphoblastic leukemia after hematopoietic stem cell transplantation publication-title: Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2018.03.015 – volume: 60 start-page: 2606 year: 2019 end-page: 21 ident: CR1 article-title: Recent advances in the treatment of acute lymphoblastic leukemia publication-title: Leuk Lymphoma doi: 10.1080/10428194.2019.1605071 – volume: 124 start-page: 188 year: 2014 end-page: 95 ident: CR12 article-title: Current concepts in the diagnosis and management of cytokine release syndrome publication-title: Blood. doi: 10.1182/blood-2014-05-552729 – volume: 98 start-page: 179 year: 2013 end-page: 84 ident: CR25 article-title: Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes publication-title: Haematologica. doi: 10.3324/haematol.2012.073189 – volume: 107 start-page: 112 year: 2020 end-page: 22 ident: CR19 article-title: CAR T-cell therapy in hematologic malignancies: a voyage in progress publication-title: Clin Pharm Ther doi: 10.1002/cpt.1674 – volume: 180 start-page: 680 year: 2018 end-page: 93 ident: CR7 article-title: Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia publication-title: Br J Haematol. doi: 10.1111/bjh.15086 – volume: 125 start-page: 3956 year: 2015 end-page: 62 ident: CR13 article-title: Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study publication-title: Blood. doi: 10.1182/blood-2015-02-627786 – volume: 385 start-page: 517 year: 2015 end-page: 28 ident: CR9 article-title: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial publication-title: Lancet. doi: 10.1016/S0140-6736(14)61403-3 – volume: 378 start-page: 439 year: 2018 end-page: 48 ident: CR10 article-title: Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia publication-title: N. Engl J Med. doi: 10.1056/NEJMoa1709866 – volume: 49 start-page: 1070 year: 2014 end-page: 5 ident: CR14 article-title: Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances publication-title: Bone Marrow Transplant. doi: 10.1038/bmt.2014.109 – volume: 189 start-page: 146 year: 2020 end-page: 52 ident: CR30 article-title: Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia publication-title: Br J Haematol. doi: 10.1111/bjh.16339 – volume: 6 start-page: 224ra25 year: 2014 ident: CR8 article-title: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia publication-title: Sci Transl Med. doi: 10.1126/scitranslmed.3008226 – volume: 14 start-page: 469 year: 2008 end-page: 77 ident: CR16 article-title: Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2008.02.007 – volume: 133 start-page: 1652 year: 2019 end-page: 63 ident: CR11 article-title: Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy publication-title: Blood. doi: 10.1182/blood-2018-11-883710 – volume: 67 start-page: e28149 year: 2020 ident: CR20 article-title: Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: opportunities for improvement publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.28149 – volume: 24 start-page: 6175 year: 2018 end-page: 84 ident: CR22 article-title: Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-18-0758 – volume: 168 start-page: 395 year: 2015 end-page: 404 ident: CR6 article-title: Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia publication-title: Br J Haematol. doi: 10.1111/bjh.13142 – volume: 120 start-page: 2032 year: 2012 end-page: 41 ident: CR5 article-title: Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation publication-title: Blood. doi: 10.1182/blood-2011-12-399287 – volume: 11 start-page: 33 year: 2018 ident: CR15 article-title: The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology publication-title: J Hematol Oncol. doi: 10.1186/s13045-018-0564-x – volume: 67 start-page: e28149 year: 2020 ident: 1236_CR20 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.28149 – volume: 12 start-page: 88 year: 2019 ident: 1236_CR18 publication-title: J Hematol Oncol doi: 10.1186/s13045-019-0781-y – volume: 378 start-page: 439 year: 2018 ident: 1236_CR10 publication-title: N. Engl J Med. doi: 10.1056/NEJMoa1709866 – volume: 94 start-page: 1113 year: 2019 ident: 1236_CR23 publication-title: Am J Hematol doi: 10.1002/ajh.25582 – volume: 20 start-page: 2023 year: 2014 ident: 1236_CR26 publication-title: Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2014.08.023 – volume: 14 start-page: e205 year: 2013 ident: 1236_CR4 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70580-6 – volume: 94 start-page: 512 year: 2019 ident: 1236_CR28 publication-title: Am J Hematol doi: 10.1002/ajh.25417 – volume: 31 start-page: 2587 year: 2017 ident: 1236_CR24 publication-title: Leukemia. doi: 10.1038/leu.2017.145 – volume: 24 start-page: 1936 year: 2018 ident: 1236_CR29 publication-title: Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2018.03.015 – volume: 24 start-page: 6175 year: 2018 ident: 1236_CR22 publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-18-0758 – volume: 180 start-page: 680 year: 2018 ident: 1236_CR7 publication-title: Br J Haematol. doi: 10.1111/bjh.15086 – volume: 124 start-page: 188 year: 2014 ident: 1236_CR12 publication-title: Blood. doi: 10.1182/blood-2014-05-552729 – volume: 385 start-page: 517 year: 2015 ident: 1236_CR9 publication-title: Lancet. doi: 10.1016/S0140-6736(14)61403-3 – volume: 120 start-page: 2032 year: 2012 ident: 1236_CR5 publication-title: Blood. doi: 10.1182/blood-2011-12-399287 – volume: 38 start-page: 595 year: 2019 ident: 1236_CR2 publication-title: Cancer Metastasis Rev. doi: 10.1007/s10555-019-09834-0 – volume: 168 start-page: 395 year: 2015 ident: 1236_CR6 publication-title: Br J Haematol. doi: 10.1111/bjh.13142 – volume: 14 start-page: 469 year: 2008 ident: 1236_CR16 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2008.02.007 – volume: 98 start-page: 179 year: 2013 ident: 1236_CR25 publication-title: Haematologica. doi: 10.3324/haematol.2012.073189 – volume: 125 start-page: 3956 year: 2015 ident: 1236_CR13 publication-title: Blood. doi: 10.1182/blood-2015-02-627786 – volume: 189 start-page: 146 year: 2020 ident: 1236_CR30 publication-title: Br J Haematol. doi: 10.1111/bjh.16339 – volume: 373 start-page: 1541 year: 2015 ident: 1236_CR3 publication-title: N Engl J Med. doi: 10.1056/NEJMra1400972 – volume: 133 start-page: 1652 year: 2019 ident: 1236_CR11 publication-title: Blood. doi: 10.1182/blood-2018-11-883710 – volume: 107 start-page: 112 year: 2020 ident: 1236_CR19 publication-title: Clin Pharm Ther doi: 10.1002/cpt.1674 – volume: 134 start-page: 2361 year: 2019 ident: 1236_CR21 publication-title: Blood. doi: 10.1182/blood.2019001641 – volume: 60 start-page: 2606 year: 2019 ident: 1236_CR1 publication-title: Leuk Lymphoma doi: 10.1080/10428194.2019.1605071 – volume: 6 start-page: 224ra25 year: 2014 ident: 1236_CR8 publication-title: Sci Transl Med. doi: 10.1126/scitranslmed.3008226 – volume: 11 start-page: 33 year: 2018 ident: 1236_CR15 publication-title: J Hematol Oncol. doi: 10.1186/s13045-018-0564-x – volume: 49 start-page: 1070 year: 2014 ident: 1236_CR14 publication-title: Bone Marrow Transplant. doi: 10.1038/bmt.2014.109 – volume: 3 start-page: 3062 year: 2019 ident: 1236_CR27 publication-title: Blood Adv. doi: 10.1182/bloodadvances.2019000593 – volume: 7 start-page: 59 year: 2014 ident: 1236_CR17 publication-title: J Hematol Oncol doi: 10.1186/s13045-014-0059-3 |
| SSID | ssj0014766 |
| Score | 2.4890304 |
| Snippet | Although chimeric antigen receptor T-cell (CAR-T) therapy produces a high complete remission rate among patients with relapsed/refractory B-cell acute... |
| SourceID | proquest gale pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 3092 |
| SubjectTerms | 13/100 631/67/1990/283/2125 692/699/1541/1990/283/2125 Acute lymphoblastic leukemia Acute lymphocytic leukemia Adolescent Antigens Cancer Cancer Research Care and treatment Cell therapy Cellular therapy Child Child, Preschool Children Chimeric antigen receptors Chromosomes Confidence intervals Critical Care Medicine Drug Resistance, Neoplasm Female Follow-Up Studies Graft vs Host Disease - etiology Graft vs Host Disease - pathology Graft vs Host Disease - therapy Graft-versus-host reaction Hematology Hematopoietic Stem Cell Transplantation - methods Hematopoietic stem cells Humans Immunotherapy, Adoptive - adverse effects Infant Intensive Internal Medicine Leukemia Leukemia in children Lymphatic leukemia Lymphoblastic leukemia in children Lymphocytes B Lymphocytes T Lymphocytic leukemia in children Male Medicine Medicine & Public Health Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - therapy Oncology Patient outcomes Patients Philadelphia Chromosome Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy Prognosis Relapse Remission Remission (Medicine) Retrospective Studies Salvage Therapy Stem cell transplantation Stem cells Survival Survival Rate Therapy Transplantation Transplantation, Haploidentical Young adults |
| Title | Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy |
| URI | https://link.springer.com/article/10.1038/s41375-021-01236-y https://www.ncbi.nlm.nih.gov/pubmed/33824464 https://www.proquest.com/docview/2586676964 https://www.proquest.com/docview/2509606846 |
| Volume | 35 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9tAEF7aBEovpe8qTdMtFHpoF1tavXwqjkkIhYQSYvBN7MuJqSKpkQzRX-6v6MxIcupAc_FFs5aWnf12dme_bxj7jJJcemIjEeixEWGknVDSaOGkViiQZjVlTE_P4pN5-GMRLfoDt7q_VjlgIgG1LQ2ekY-CKKXrmHH4vfotsGoUZlf7EhqP2S5Kl6FXJ4vNhssPky5XiRMpho1GT5oZy3RUA3gnyE3GzXQgY9FuLUz34fmf9elewpTWoePn7FkfQPJpN-Iv2CNXvGRPTvsU-Sv2Z16gpAWV5XKWX6kqL1fExoXR4CTRWlblCrmLHEWcOR7d84Y0znPVEZEKvqq5Kri7pXP9ouElIQuHCJcP9G8wsLxFsOAk4sGRFlPVzo6gbzdUxqfleF6DQpTV1UpBS7z7V5fXThTukhTH-aGg9yuzbhzPW_CtUkNAj1-Xu_Uvdw3tqI45n03PxUVn3ZHG2tdsfnx0MTsRfUEHYcJENmJpIhMBjAQq8bG8NfhIEjsMEWxkltIl1k60sqkam3AS2CWCQ-qMjVXk4tRa-YbtFGXh3jHoWKy0VTaBHRtgkNa-tWEyMWPfpEuZGI_5w2hmplc7x6IbeUZZd5lmnQdk4AEZeUDWeuzrpk3VaX08aP0RnSTr-KoboMimcYp6UX7ge-wLWSBUwLuN6hkP0AMU3dqy3N-yhCluth8Pjpj1EFNndxPCY582j7ElXpsrXLlGG9qhQozpsbedA296JmUKoR22_jZ49N2f_7_bew9_y3v2NMBJRWzNfbbT3KzdBwjbGn1AcxN-05l_wHYPj85-nv8FjslGVQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkIAXxJ3AYEYC8QBWmzi3PiBUClPH1j2gVtqb8a2sokvCkgryp_hh_ArOcZKOTmJve85xYsufz7Fz_H2HkJcoyaUGJmKB6msWRsoyybViliuJAmlGuYzp5Cgez8LPx9HxFvndcWHwWmXnE52jNrnGf-S9IErddcw4fF_8YFg1CrOrXQmNBhYHtv4JR7by3f5HmN9XQbD3aToas7aqANNhwis215GOAMuBTHyssQwdTWKLccpEes5tYsxASZPKvg4HgZkjQlOrTSwjG6fGcHjvNXI95LA0kZk-Wl8p8cOkyY3iwo3hYNOSdPo87ZUQLBLkQuPhPeAxqzcC4cVw8E88vJCgdXFv7w653W5Y6bBB2F2yZbN75MakTcnfJ39mGUpouDJg1tATWSzzhWP_wuxTJwmbF_kCuZIURaMppgpo5TTVl7IhPmV0UVKZUfvL5RGyiubOk1HYUdOObg4GhtbonKgTDaFIwylKa3owtjNXNqim-H8IhS-Lk4WElnjXsMxPLcvsN6dwTj8w932pV5WlyxqwnCs4QGDvlnb13Z5CO1c3nY6GX9i0sW5IavUDMruSqX5ItrM8s48JDCyWykiTwAkRfJ5SvjFhMtB9X6dznmiP-N1sCt2qq2ORj6VwWX6eigYBAhAgHAJE7ZE36zZFoy1yqfUugkQ0_Ni1YxLDOEV9Kj_wPfLaWaBrgm9r2TIsYAQo8rVhubNhCS5Fbz7ugChal1aK8wXokRfrx9gSr-llNl-hjTsRw57WI48aAK9HxnkKW0ls_bZD9PnL_z_sJ5f3ZZfcHE8nh-Jw_-jgKbkV4AJzTNEdsl2drewz2DJW6rlbp5R8vWrH8BezW4FD |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKkSouiH8WCjUSiANYu4mT2HtAaNlStZRWCHWl3lL_LV2xTUKTFeTVeCSeghkn2bKV6K3njBNb_jzjycx8Q8hLpOTSQxuzUA8Mi2LtmOJGM8e1QoI0q33E9OAw2Z1En47j4zXyu6uFwbTKTid6RW1zg__I-2EsfTpmEvWnbVrEl-2d98UPhh2kMNLatdNoILLv6p_gvpXv9rZhr1-F4c7Ho_EuazsMMBMJXrGpiU0MuA6VCLDfMkxaJA5tlo3NlDth7VArK9XARMPQThGt0hmbqNgl0loO771BbgouJJ4xOV6mlwSRaOKkeIgTcHLagp0Bl_0SDIfAumh05EOesHrFKF42Df_YxkvBWm8Dd-6Q2-3llY4atN0lay67RzYO2vD8ffJnkiGdhm8J5iw9VcU8n_lKYEAC9fSweZHPsG6SIoE0xbABrTy_-lw1RVAZnZVUZdT98jGFrKK512oUbte0Kz0HAUtrVFTUE4hQLMkpSmf7sLZz30KopvivCEkwi9OZgpGYd1jmZ45l7ptnO6cfmP--MovK0XkNuM41OBM4u7lbfHdnMM73UKfj0Vd21Eg3BWv1AzK5lq1-SNazPHOPCSwsUdoqK8BbBP2ndWBtJIZmEBg55cL0SNDtZmpapnVs-DFPfcSfy7RBQAoISD0C0rpH3izHFA3PyJXSWwiStKmVXSqpdJRI5KoKwqBHXnsJVFPwbaPaagtYARJ-rUhurkiCejGrjzsgpq16K9OLw9gjL5aPcSSm7GUuX6CM947hftsjjxoAL1fGuYRrJY5-2yH64uX_X_aTq-eyRTZAJaSf9w73n5JbIZ4vXzS6Sdar84V7BrfHSj_3x5SSk-vWC38BoSiFeQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Unmanipulated+haploidentical+hematopoietic+stem+cell+transplantation+is+an+excellent+option+for+children+and+young+adult+relapsed%2Frefractory+Philadelphia+chromosome-negative+B-cell+acute+lymphoblastic+leukemia+after+CAR-T-cell+therapy&rft.jtitle=Leukemia&rft.au=Hu%2C+Guan-Hua&rft.au=Zhao%2C+Xiang-Yu&rft.au=Zuo%2C+Ying-Xi&rft.au=Chang%2C+Ying-Jun&rft.date=2021-11-01&rft.pub=Nature+Publishing+Group&rft.issn=0887-6924&rft.volume=35&rft.issue=11&rft.spage=3092&rft_id=info:doi/10.1038%2Fs41375-021-01236-y&rft.externalDocID=A680437121 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0887-6924&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0887-6924&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0887-6924&client=summon |